Literature DB >> 18302714

Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index.

Katrin Hoffmann1, Martin J Firth, Alex H Beesley, Joseph R Freitas, Jette Ford, Saranga Senanayake, Nicholas H de Klerk, David L Baker, Ursula R Kees.   

Abstract

Despite high cure rates 25% of children with acute lymphoblastic leukaemia (ALL) relapse and have dismal outcome. Crucially, many are currently stratified as standard risk (SR) and additional markers to improve patient stratification are required. Here we have used diagnostic bone marrow specimens from 101 children with pre-B ALL to examine the use of gene expression profiles (GEP) as predictors of long-term clinical outcome. Patients were divided into two cohorts for model development and validation based on availability of specimen material. Initially, GEP from 55 patients with sufficient material were analysed using HG-U133A microarrays, identifying an 18-gene classifier (GC) that was more predictive of outcome than conventional prognostic parameters. After feature selection and validation of expression levels by quantitative reverse transcription polymerase chain reaction (qRT-PCR), a three-gene qRT-PCR risk index [glutamine synthetase (GLUL), ornithine decarboxylase antizyme inhibitor (AZIN), immunoglobulin J chain (IGJ)] was developed that predicted outcome with an accuracy of 89% in the array cohort and 87% in the independent validation cohort. The data demonstrate the feasibility of using GEP to improve risk stratification in childhood ALL. This is particularly important for the identification of patients destined to relapse despite their current stratification as SR, as more intensive front-line treatment options for these individuals are already available.

Entities:  

Mesh:

Year:  2008        PMID: 18302714     DOI: 10.1111/j.1365-2141.2008.06981.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

1.  An empirical assessment of validation practices for molecular classifiers.

Authors:  Peter J Castaldi; Issa J Dahabreh; John P A Ioannidis
Journal:  Brief Bioinform       Date:  2011-02-07       Impact factor: 11.622

2.  Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.

Authors:  Huining Kang; I-Ming Chen; Carla S Wilson; Edward J Bedrick; Richard C Harvey; Susan R Atlas; Meenakshi Devidas; Charles G Mullighan; Xuefei Wang; Maurice Murphy; Kerem Ar; Walker Wharton; Michael J Borowitz; W Paul Bowman; Deepa Bhojwani; William L Carroll; Bruce M Camitta; Gregory H Reaman; Malcolm A Smith; James R Downing; Stephen P Hunger; Cheryl L Willman
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

3.  Extended exposure to dietary melatonin reduces tumor number and size in aged male mice.

Authors:  Edward H Sharman; Kaizhi G Sharman; Stephen C Bondy
Journal:  Exp Gerontol       Date:  2010-09-16       Impact factor: 4.032

4.  Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine.

Authors:  Claudia Stäubert; Hasanuzzaman Bhuiyan; Anna Lindahl; Oliver Jay Broom; Yafeng Zhu; Saiful Islam; Sten Linnarsson; Janne Lehtiö; Anders Nordström
Journal:  J Biol Chem       Date:  2015-02-19       Impact factor: 5.157

5.  Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study.

Authors:  Amanda L Cleaver; Alex H Beesley; Martin J Firth; Nina C Sturges; Rebecca A O'Leary; Stephen P Hunger; David L Baker; Ursula R Kees
Journal:  Mol Cancer       Date:  2010-05-12       Impact factor: 27.401

6.  Validation of a mouse xenograft model system for gene expression analysis of human acute lymphoblastic leukaemia.

Authors:  Amy L Samuels; Violet K Peeva; Rachael A Papa; Marin J Firth; Richard W Francis; Alex H Beesley; Richard B Lock; Ursula R Kees
Journal:  BMC Genomics       Date:  2010-04-21       Impact factor: 3.969

7.  Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment.

Authors:  Matheus Dyczynski; Mattias Vesterlund; Ann-Charlotte Björklund; Vasilios Zachariadis; Jerry Janssen; Hector Gallart-Ayala; Evangelia Daskalaki; Craig E Wheelock; Janne Lehtiö; Dan Grandér; Katja Pokrovskaja Tamm; Roland Nilsson
Journal:  Cell Death Dis       Date:  2018-08-28       Impact factor: 8.469

8.  Ornithine decarboxylase antizyme inhibitor 2 (AZIN2) is a signature of secretory phenotype and independent predictor of adverse prognosis in colorectal cancer.

Authors:  Tuomas Kaprio; Tiina Rasila; Jaana Hagström; Harri Mustonen; Petri Lankila; Caj Haglund; Leif C Andersson
Journal:  PLoS One       Date:  2019-02-15       Impact factor: 3.240

9.  Early diagnosis of colorectal cancer via plasma proteomic analysis of CRC and advanced adenomatous polyp.

Authors:  Setareh Fayazfar; Hakimeh Zali; Afsaneh Arefi Oskouie; Hamid Asadzadeh Aghdaei; Mostafa Rezaei Tavirani; Ehsan Nazemalhosseini Mojarad
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2019

10.  Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism.

Authors:  A H Beesley; M J Firth; J Ford; R E Weller; J R Freitas; K U Perera; U R Kees
Journal:  Br J Cancer       Date:  2009-05-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.